image
Healthcare - Medical - Instruments & Supplies - NASDAQ - US
$ 21.22
-1.39 %
$ 1.01 B
Market Cap
-111.68
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one BLFS stock under the worst case scenario is HIDDEN Compared to the current market price of 21.2 USD, BioLife Solutions, Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one BLFS stock under the base case scenario is HIDDEN Compared to the current market price of 21.2 USD, BioLife Solutions, Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one BLFS stock under the best case scenario is HIDDEN Compared to the current market price of 21.2 USD, BioLife Solutions, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart BLFS

image
$29.0$29.0$28.0$28.0$27.0$27.0$26.0$26.0$25.0$25.0$24.0$24.0$23.0$23.0$22.0$22.0$21.0$21.0$20.0$20.0Jan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 Jun
FINANCIALS
82.3 M REVENUE
-42.59%
-7.13 M OPERATING INCOME
89.93%
-20.2 M NET INCOME
69.61%
8.43 M OPERATING CASH FLOW
167.46%
58.3 M INVESTING CASH FLOW
226.85%
-6.78 M FINANCING CASH FLOW
-64.04%
23.9 M REVENUE
799.21%
-1.22 M OPERATING INCOME
-87.88%
-448 K NET INCOME
-3.60%
1.73 M OPERATING CASH FLOW
4.98%
-27.2 M INVESTING CASH FLOW
-36.91%
-2.99 M FINANCING CASH FLOW
26.77%
Balance Sheet BioLife Solutions, Inc.
image
Current Assets 149 M
Cash & Short-Term Investments 105 M
Receivables 9.17 M
Other Current Assets 35 M
Non-Current Assets 251 M
Long-Term Investments 995 K
PP&E 16.8 M
Other Non-Current Assets 233 M
26.18 %8.76 %4.19 %58.32 %Total Assets$399.5m
Current Liabilities 32.7 M
Accounts Payable 3.57 M
Short-Term Debt 12.5 M
Other Current Liabilities 16.7 M
Non-Current Liabilities 17.8 M
Long-Term Debt 17.7 M
Other Non-Current Liabilities 124 K
7.06 %24.62 %33.03 %35.03 %Total Liabilities$50.6m
EFFICIENCY
Earnings Waterfall BioLife Solutions, Inc.
image
Revenue 82.3 M
Cost Of Revenue 24.5 M
Gross Profit 57.8 M
Operating Expenses 60.8 M
Operating Income -7.13 M
Other Expenses 13.1 M
Net Income -20.2 M
100m100m80m80m60m60m40m40m20m20m00(20m)(20m)(40m)(40m)82m(25m)58m(61m)(7m)(13m)(20m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
70.21% GROSS MARGIN
70.21%
-8.67% OPERATING MARGIN
-8.67%
-24.54% NET MARGIN
-24.54%
-5.78% ROE
-5.78%
-5.05% ROA
-5.05%
-1.87% ROIC
-1.87%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis BioLife Solutions, Inc.
image
10m10m5m5m00(5m)(5m)(10m)(10m)(15m)(15m)(20m)(20m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -20.2 M
Depreciation & Amortization 8.66 M
Capital Expenditures -3.23 M
Stock-Based Compensation 30.9 M
Change in Working Capital 0
Others -11.1 M
Free Cash Flow 5.2 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets BioLife Solutions, Inc.
image
Wall Street analysts predict an average 1-year price target for BLFS of $30 , with forecasts ranging from a low of $30 to a high of $30 .
BLFS Lowest Price Target Wall Street Target
30 USD 41.38%
BLFS Average Price Target Wall Street Target
30 USD 41.38%
BLFS Highest Price Target Wall Street Target
30 USD 41.38%
Price
Max Price Target
Min Price Target
Average Price Target
3030282826262424222220201818Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 12
6. Ownership
Insider Ownership BioLife Solutions, Inc.
image
Sold
0-3 MONTHS
25.3 M USD 7
3-6 MONTHS
989 K USD 7
6-9 MONTHS
3.62 M USD 6
9-12 MONTHS
243 K USD 6
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
How Much Upside is Left in BioLife Solutions (BLFS)? Wall Street Analysts Think 41.72% The average of price targets set by Wall Street analysts indicates a potential upside of 41.7% in BioLife Solutions (BLFS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. zacks.com - 2 weeks ago
BioLife Solutions to Participate in Upcoming Investor Conferences in May and June 2025 BOTHELL, Wash. , May 14, 2025 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") market, today announced the company will be participating in the following investor conferences: 22nd Annual Craig-Hallum Institutional Investor Conference May 28, 2025 Minneapolis, MN at the Renaissance Hotel Benchmark 2025 Healthcare House Call Virtual Conference May 29, 2025 Virtual Jefferies Global Life Sciences Conference June 3 – 5, 2025 New York, NY at the Marriott Marquis Wolfe Research Small & Mid-Cap Conference June 5, 2025 New York, NY at Wolfe Headquarters Northland Growth Conference 2025 June 25, 2025 Virtual About BioLife Solutions BioLife Solutions is a leading developer and supplier of bioproduction products and services for the cell and gene therapy (CGT) and broader biopharma markets. prnewswire.com - 1 month ago
Can BioLife Solutions (BLFS) Climb 30.68% to Reach the Level Wall Street Analysts Expect? The consensus price target hints at a 30.7% upside potential for BioLife Solutions (BLFS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. zacks.com - 1 month ago
BioLife Solutions, Inc. (BLFS) Q1 2025 Earnings Call Transcript BioLife Solutions, Inc. (NASDAQ:BLFS ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Troy Wichterman - Chief Financial Officer Roderick de Greef - Chairman and Chief Executive Officer Conference Call Participants Matthew Stanton - Jefferies Paul Knight - KeyBanc Chad Wiatrowski - TD Cowen Thomas Flaten - Lake Street Matthew Hewitt - Craig-Hallum Capital Group Carl Byrnes - Northland Capital Markets Yi Chen - H.C. Wainwright Operator Good afternoon, ladies and gentlemen, and thank you for standing by. seekingalpha.com - 1 month ago
BioLife Solutions, Inc. (BLFS) Q1 Earnings and Revenues Beat Estimates BioLife Solutions, Inc. (BLFS) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of a loss of $0.03 per share. This compares to loss of $0.19 per share a year ago. zacks.com - 1 month ago
BioLife Solutions Updates Earnings Call Information BOTHELL, Wash. , May 8, 2025 /PRNewswire/ -- BioLife Solutions, Inc.  (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of cell processing tools and services for the cell and gene therapy ("CGT") market, is announcing corrected call-in numbers for their Earnings Call this afternoon at 4:30pm ET. prnewswire.com - 1 month ago
BioLife Solutions Reports First Quarter 2025 Financial Results Cell Processing revenue of $21.6 million, up 33% over Q1 2024 GAAP gross margin of 63%  and non-GAAP adjusted gross margin of 66% GAAP net loss of $0.4 million and non-GAAP adjusted EBITDA of $5.7 million or 24% of revenue Conference call begins at 4:30 p.m. Eastern time today BOTHELL, Wash. prnewswire.com - 1 month ago
Stock Picks From Seeking Alpha's April 2025 New Analysts In April, Seeking Alpha welcomed 20 new analysts. This article introduces them and showcases some of their top picks. Top picks include Palantir, Arch Capital Group, and Utah Medical Products, emphasizing an under-recognized growth driver, discounted valuation, and a substantial margin of safety. Analysts also highlighted Sell recommendations on Estée Lauder and Intuitive Surgical, citing deteriorating consumer sentiment and little price upside. seekingalpha.com - 1 month ago
BioLife Solutions to Report First Quarter 2025 Financial Results and Business Update on May 8, 2025 BOTHELL, Wash. , April 30, 2025 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") market, today announced the Company's first quarter 2025 financial results will be released after market close on Thursday, May 8, 2025. prnewswire.com - 1 month ago
BioLife Solutions Acquires PanTHERA CryoSolutions to Advance Leadership as a Pure Play Bioproduction Consumables Company Strategic acquisition enhances biopreservation media portfolio with novel Ice Recrystallization Inhibitor technology Marks the second acquisition from Bioproduction Innovation Accelerator program BOTHELL, Wash. , April 7, 2025 /PRNewswire/ --  BioLife Solutions , Inc. (NASDAQ: BLFS ) ("BioLife" or the "Company"), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") market, today announced the acquisition of privately-held PanTHERA CryoSolutions, Inc., ("PanTHERA"), a developer of novel cryopreservation solutions based on proprietary Ice Recrystallization Inhibitor ("IRI") technology. prnewswire.com - 2 months ago
BioLife Solutions: A Steady Stock Lined Up For Success In A Booming Industry BioLife Solutions, an established biotech firm, is poised to benefit from the booming cell and gene therapy sector, projected to grow significantly by 2030. Despite recent negative EPS, BioLife has consistently exceeded earnings expectations, indicating strong future potential and investor confidence. BioLife's unique focus on cell preservation and storage positions it advantageously within the CGT sector, with expected revenue growth heavily outpacing peers. seekingalpha.com - 2 months ago
5 Low-Leverage Stocks to Buy Amid Trump's Tariff Woes The majority of U.S. stock indices ended barely in the green on March 21, 2025, overcoming their recent losing streaks since investors remain wary about the long-term economic impacts of President Trump's enhanced import tariffs. The latest uptick in the major stock indices was mostly because the Federal Reserve kept its projection for interest rate cuts broadly unchanged, indicating economic stability for the time being. zacks.com - 2 months ago
8. Profile Summary

BioLife Solutions, Inc. BLFS

image
COUNTRY US
INDUSTRY Medical - Instruments & Supplies
MARKET CAP $ 1.01 B
Dividend Yield 0.00%
Description BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; and the ThawSTAR line that includes automated vial and cryobag thawing products that control the heat and timing of the thawing process of biologic materials. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage services. It markets and sells its products directly, as well as through third party distributors. BioLife Solutions, Inc. was incorporated in 1987 and is headquartered in Bothell, Washington.
Contact 3303 Monte Villa Parkway, Bothell, WA, 98021 https://www.biolifesolutions.com
IPO Date Nov. 22, 1989
Employees 159
Officers Mr. Todd Berard Chief Commercial Officer Mr. Roderick de Greef Chief Executive Officer & Chairman Mr. Troy Wichterman CPA Chief Financial Officer Ms. Sarah Aebersold J.D. Chief Human Resources Officer Mr. Sean Werner Ph.D. Chief Technology Officer Ms. Karen Foster Chief Quality & Operations Officer Dr. Aby J. Mathew Ph.D. Chairman of Scientific Advisory Board, Executive Vice President & Chief Scientific Officer